Table 2.
Ranking of interventions with respect to all-cause and cancer-related mortality, adverse gastrointestinal and genitourinary events: SUCRA values and median ranks (with 95% intervals)*
| Intervention | All-cause mortality |
Cancer-related mortality |
Adverse gastrointestinal events |
Adverse genitourinary events |
||||
|---|---|---|---|---|---|---|---|---|
| SUCRA value (%) | Median rank (95% interval) | SUCRA value (%) | Median rank (95% interval) | SUCRA value (%) | Median rank (95% interval) | SUCRA value (%) | Median rank (95% interval) | |
| Observational management | 18 | 7 (2 to 8) | 30 | 6 (3 to 8) | – | – | – | – |
| Prostatectomy | 49 | 5 (1 to 7) | 64 | 4 (1 to 7) | – | – | – | – |
| Conventional radiotherapy | 35 | 6 (2 to 8) | 16 | 7 (4 to 8) | 43 | 4 (2 to 6) | 51 | 3 (1 to 6) |
| Conventional radiotherapy hypofractionated | 58 | 4 (1 to 8) | 44 | 5 (1 to 8) | 42 | 4 (1 to 6) | 50 | 3 (1 to 6) |
| Conformal LD radiotherapy | 57 | 4 (1 to 7) | 61 | 4 (2 to 7) | 67 | 2 (2 to 4) | 66 | 3 (1 to 5) |
| Conformal HD radiotherapy | 63 | 3 (1 to 7) | 75 | 2 (1 to 6) | 19 | 5 (3 to 6) | 30 | 5 (2 to 6) |
| Conformal LD radiotherapy hypofractionated | 69 | 1 (1 to 8) | 85 | 1 (1 to 8) | 30 | 5 (2 to 6) | 26 | 5 (1 to 6) |
| Cryotherapy | 50 | 4 (1 to 8) | 24 | 7 (2 to 8) | 99 | 1 (1 to 2) | 77 | 1 (1 to 6) |
*The SUCRA value is a numerical summary of the estimated probabilities that each treatment is the best, second best, third best (and so on) for that particular outcome. Higher values indicate higher rankings compared with other treatments. For example, for cryotherapy, the high SUCRA value of 99% and median rank of 1 for adverse gastrointestinal events shows that cryotherapy is expected to be superior with respect to this outcome.
HD, high dose; LD, low dose; SUCRA, Surface Under the Cumulative RAnking curve.